Inhibition of the PI3K/AKT/mTOR pathway activates autophagy and compensatory Ras/Raf/MEK/ERK signalling in prostate cancer.

Butler, Dominika E; Marlein, Christopher; Walker, Hannah F; Frame, Fiona M; Mann, Vincent M; Simms, Matthew S; Davies, Barry R; Collins, Anne T; Maitland, Norman J

Butler, Dominika E; Marlein, Christopher; Walker, Hannah F; Frame, Fiona M; Mann, Vincent M; Simms, Matthew S; Davies, Barry R; Collins, Anne T; Maitland, Norman J.

Afiliación

Butler DE; The Cancer Research Unit, Department of Biology, University of York, York YO10 5DD, UK.
Marlein C; Norwich Medical School, University of East Anglia, Norwich NR4 7TJ, UK.
Walker HF; The Cancer Research Unit, Department of Biology, University of York, York YO10 5DD, UK.
Frame FM; The Cancer Research Unit, Department of Biology, University of York, York YO10 5DD, UK.
Mann VM; Gastroenterology Research Department, Hull Royal Infirmary, Hull HU3 2JZ, UK.
Simms MS; Department of Urology, Castle Hill Hospital (Hull & East Yorkshire Hospital NHS Trust), Cottingham HU16 5JQ, UK.
Davies BR; Hull York Medical School, University of York, York YO10 5DD, UK.
Collins AT; AstraZeneca, Cancer Research UK Cambridge Institute, Cambridge CB2 0RE, UK.
Maitland NJ; The Cancer Research Unit, Department of Biology, University of York, York YO10 5DD, UK.

Oncotarget ; 8(34): 56698-56713, 2017 Aug 22.

Article en En | MEDLINE | ID: mdl-28915623

Palabras clave

AKT; MAPK signalling; RAS; autophagy; mTOR; prostate cancer

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Oncotarget Año: 2017 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google